CSIMarket
Company Name or Ticker Symbol
Search for other Categories
 


Nanoviricides, Inc.  (NNVC)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
 

Nanoviricides's Quick Ratio

NNVC's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Select the Comparisons : Select the Ratio:                        

NNVC Quick Ratio (Mar 31 2017)
III. Quarter
(Dec 31 2016)
II. Quarter
(Sep 30 2016)
I. Quarter
(Jun 30 2016)
IV. Quarter
(Mar 31 2016)
III. Quarter
Y / Y Current Liabilities Change -94.99 % 330.66 % 605.82 % 1022.32 % 1164.65 %
Y / Y Cash & cash equivalent Change -36.89 % -31.63 % -25.66 % -23.2 % -24.52 %
Quick Ratio MRQ 48.73 3.06 3.16 3.58 3.87
Overall Ranking # 57 # 0 # 57 # #
Seq. Current Liabilities Change -94.75 % -8.98 % 2.89 % 1.89 % 351.33 %
Seq. Cash & cash equivalent Change -16.3 % -11.92 % -9.31 % -5.61 % -9.33 %



Quick Ratio third quarter 2017 Comment
Current Liabilities decreased faster than Nanoviricides's Cash & cash equivalent, this led to improvement in Nanoviricides's Quick Ratio to 48.73, Quick Ratio remained below Nanoviricides, Inc. average.

Within Medical Laboratories industry Nanoviricides, Inc. achieved highest Quick Ratio than Nanoviricides in third quarter 2017. While total ranking remained unchanged compare to previous quarter at no. .

Explain Quick Ratio?
What are NNVC Segments?
See Quick Ratio NNVC on the trailing twelve month basis
Quick Ratio third quarter 2017 Company Ranking
Within: No.
Medical Laboratories Industry # 1
Healthcare Sector # 4
Overall Market # 57


Quick Ratio Statistics
High Average Low
64.81 21.42 3.06
(Mar 31 2015)   (Dec 31 2016)


You need to upgrade your Flash Player


Financial Statements
Nanoviricides's Current Liabilities $ 0 Millions Visit NNVC's Balance sheet
Nanoviricides's Cash & cash equivalent $ 16 Millions Visit NNVC's Balance sheet
Source of NNVC's Sales Visit NNVC's Sales by Geography




Companies with similar Quick Ratio in the quarter endingMar 31 2017, within Medical Laboratories Industry Quick RatioMar 31 2017 MRQ Cash & cash equivalentMar 31 2017 MRQ Current Liabilities
Nanoviricides, Inc.  48.73 $ 16.159  Millions$ 0.332  Millions
Cascadian Therapeutics, Inc.  24.59 $ 125.889  Millions$ 5.119  Millions


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2017 CSIMarket, Inc. All rights reserved. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)
Intraday Data provided by Barchart and subject to terms of use. To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Stock Price, historical and current end-of-day data provided by eoddata. Intraday data delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Barchart and Eoddata. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com